A Phase II Study of Axitinib in Advanced Carcinoid Tumors.
Phase of Trial: Phase II
Latest Information Update: 25 Apr 2018
At a glance
- Drugs Axitinib (Primary)
- Indications Carcinoid tumour; Neuroendocrine tumours
- Focus Therapeutic Use
- 19 Mar 2018 Status changed from active, no longer recruiting to completed.
- 09 Jan 2018 Planned End Date changed from 30 Jun 2018 to 1 Jan 2019.
- 30 Aug 2017 Planned End Date changed from 31 Dec 2017 to 30 Jun 2018.